In June 1937, a salesman for the S. E. Massengill Company reported demand in the southern states for sulfanilamide in liquid ...
Scarboro contends these findings should be treated as design information rather than as a sign that patients need more ...
Companies showcasing equipment and services at the event include Shilpa Biologicals (Booth 12J33), which is announcing the ...
Access Part 1 of this interview, in which Piervincenzi explains how benchmarking could reward reliable generic drug suppliers ...
The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...
Machine-readable digital standards integrated into LIMS, ELNs, and regulatory platforms reduce transcription risk, streamline ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps. When Merck and Moderna's INTerpath-001 trial of ...
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions ...
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence. The FDA's September 22 direct final rule, which swaps ...
Understand why the FDA's shift toward single pivotal Phase III trials requires establishing a drug's mechanistic hypothesis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results